Business context and reporting period
InnovAge Holding Corp. operates a single reportable PACE business, providing coordinated medical and support services to frail seniors under capitated Medicare and Medicaid arrangements. This filing covers the quarter ended March 31, 2024—the company’s fiscal 2024 third quarter—and the nine months then ended; this differs from the “2023 Q3” period in the request metadata. At quarter-end, InnovAge served approximately 6,820 participants through 19 centers in six states.
Financial performance and liquidity
| Metric | Three months ended March 31, 2024 | Nine months ended March 31, 2024 |
|---|---|---|
| Revenue | $193.1 million | $564.5 million |
| Operating loss | $5.8 million | $18.3 million |
| Net loss | $6.2 million | $21.0 million |
| Net loss attributable to InnovAge | $5.9 million | $19.6 million |
| Adjusted EBITDA (non-GAAP) | $3.6 million | $13.6 million |
Quarterly revenue increased 11.9% year over year; nine-month revenue increased 10.4%. For the nine-month period, capitation revenue rose 10.4%, reflecting higher rates and member months. External provider costs increased 7.4%, and care costs excluding depreciation and amortization increased 6.1%. Nine-month center-level contribution margin was $95.5 million, or 16.9% of revenue, versus $72.8 million, or 14.2%, a year earlier. The nine-month GAAP net loss margin was 3.7%; Adjusted EBITDA margin was 2.4%.
Cash and cash equivalents were $54.1 million and short-term investments were $45.2 million at March 31, 2024. Current assets were $153.1 million against current liabilities of $122.0 million. Debt principal totaled $66.9 million, including $64.7 million under the term loan; the term-loan rate was 7.16%. The company had no revolver borrowings and $96.0 million of available capacity, subject to covenants and other borrowing conditions. It reported covenant compliance. Operating and finance lease liabilities totaled $45.8 million.
For the nine months, operating cash flow was negative $38.8 million, investing cash flow negative $27.3 million, and financing cash flow negative $7.1 million. Cash, cash equivalents and restricted cash declined $73.2 million. The company attributed the operating cash outflow principally to timing of receipts, higher receivables, and the reduction in deferred revenue; investing outflows included the $23.9 million Concerto acquisition and $4.6 million of property and equipment purchases.
Material changes versus the prior comparable period
- Nine-month net loss narrowed to $21.0 million from $31.6 million; operating loss narrowed to $18.3 million from $38.5 million. Adjusted EBITDA improved from negative $2.0 million to positive $13.6 million, a non-GAAP measure that includes specified addbacks.
- Participant census increased to 6,820 from 6,310, and centers increased to 19 from 17. Nine-month member months rose 3.0%.
- Cost pressure continued: higher wages, staffing, transportation, pharmacy, assisted-living utilization and provider rates partly offset revenue growth. Sales and marketing expense rose 36.4% for the nine months, while corporate, general and administrative expense fell 5.7%.
- Cash and cash equivalents fell from $127.2 million at June 30, 2023, including the effect of the Concerto acquisition and timing of cash receipts. The nine-month comparison also includes a prior-year deferred-revenue cash-flow benefit and a larger prior-year income-tax benefit.
Outlook, commentary, risks and unusual items
- Management believes available cash, operating cash flows and financing sources are sufficient for operating and capital needs for the next 12 months and beyond, but cautions that assumptions may prove inaccurate. No specific financial guidance was provided in the supplied filing text.
- Growth plans include expanding enrollment, opening centers and integrating acquisitions. Tampa opened in January 2024 and Orlando opened April 1, 2024. The two California planned de novo centers, Downey and Bakersfield, remain unable to open while DHCS attestations are suspended pending remediation and review.
- DHCS issued final findings from its Sacramento audit in February 2024; the company submitted a corrective action plan in March. CMS released the company from its approved plan and closed its portion of the audit in April, while the state process remained ongoing. DHCS was also conducting a medical review of San Bernardino.
- Key risks include government audits and investigations, potential regulatory action, accuracy of risk-adjustment submissions, cost of care exceeding capitation, labor shortages and wage inflation, eligibility-processing delays, and reliance on Medicare and Medicaid. Federal and state civil investigative demands concerning billing and care practices remain unresolved. A securities class action is in discovery; a related derivative case is stayed. The company says it cannot predict the outcomes of these matters.
- Pennsylvania center nurses voted to unionize, representing approximately 1% of the workforce; collective bargaining began in late March. California’s SB 525 may raise costs through affected contractors and providers, although PACE centers themselves are not covered by the law.
- The company recognized a $2.0 million nine-month impairment loss on its Jetdoc minority investment. It also agreed to a $1.3 million California wage-and-hour settlement, approved by the court April 2, 2024, with payment expected in fiscal Q4. After quarter-end, Pinewood Lodge sold its senior-housing property for $9.5 million on May 2, 2024.
- Management concluded disclosure controls were effective as of March 31, 2024 and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Progress and potential financial or operating consequences of the Sacramento remediation, San Bernardino review, and suspended California de novo attestations.
- Whether enrollment growth, retention and capitation-rate increases can outpace medical costs, labor expense and provider-rate increases.
- The drivers and sustainability of negative operating cash flow, including receivable collections and the absence of prior-period deferred-revenue timing benefits.
- Liquidity after acquisition, capital spending and lease commitments, and continued compliance with debt covenants.
- Developments in the DOJ and Colorado investigations, securities litigation, and settlement payment; also confirm the subsequent Pinewood Lodge sale’s net proceeds and distribution.